Failed I-PRESERVE trial highlights need for new approach in heart failure
This article was originally published in Scrip
Executive Summary
New approaches are needed to treat heart failure in the 50% of patients who have a normal or near normal left ventricular ejection fraction, experts say after the failure of the I-PRESERVE trial ofBristol-Myers Squibb/Sanofi-Aventis's angiotensin II receptor blocker irbesartan (Aprovel).